Vitronectin (Vn), a multifunctional protein of blood and extracellular matrix, interacts with complement C9. This interaction may modulate innate immunity. Details of Vn-C9 interactions are limited. Vn-C9 interactions were assessed by employing a goat homologous system and observing Vn binding to C9 in three different assays. Using recombinant fragments, C9 binding was mapped to the N-terminus of Vn. Site directed mutagenesis was performed to alter the second arginine glycine aspartic acid (RGD) sequence (RGD-2) of Vn. Changing R to G or D to A in RGD-2 caused significant decrease in Vn binding to C9 whereas changing of R to G in the first RGD motif (RGD-1) had no effect on Vn binding to C9. These results imply that the RGD-2 of goat Vn is involved in C9 binding. In a competitive binding assay, the presence of soluble RGD peptide inhibited Vn binding to C9 whereas heparin had no effect. Vn binding to C9 was also evaluated in terms of bacterial pathogenesis. Serum dependent inhibition of Escherichia coli growth was significantly reverted when Vn or its N-fragment were included in the assay. The C-fragment, which did not support C9 binding, also partly nullified serum-dependent inhibition of bacterial growth, probably through other serum component(s).
Complement proteins are key components of the host innate immunity. The complement C9, which forms a part of the terminal membrane attack complex, is responsible for bacterial lysis by forming pores in their membranes (1) . Bacteria can subvert complement attack by binding to complement inhibitors such as C4b-binding proteins and factor H. Furthermore, binding of many bacteria to the terminal complement pathway inhibitor, Vn, has been documented (2, 3) .
Vitronectin, a multifunctional protein, is present in blood and extracellular matrix. It is involved in diverse body functions such as angiogenesis, cell adhesion and migration and tissue repair (4, 5) . The various functions of Vn are attributable to its structural features. The RGD motif, which is in the N-terminal part of Vn, is involved in cell binding. At least three heparin binding regions are predicated in human Vn, namely residues 82-137, 175-219 and 348-361 (6) . In blood, Vn is mainly in the monomer form, whereas in the extracellular matrix it is multimeric. Vn functions are also governed by its conformational state, which may be folded (native monomeric state) or unfolded (multimeric and may be partially denatured state) (7) .
Vn binding to bacteria may serve multiple functions. First, the presence of Vn on the bacterial surface may disguise the host immune effector system. Second, Vn may act as a bridge between the bacteria and host cell, leading to bacterial colonization. The protein may modulate host innate immunity by interacting with complement components, notably the membrane attack complex (8) . Vn interactions with complement proteins are not well understood. Vn may bind to C5b-7 complex through a non-heparin binding site (9) ; this interaction may inhibit membrane insertion by C5b-7 complex. Furthermore, Vn binding to C9 may involve the heparin binding domain (10) . This binding may prevent C9 polymerization and membrane pore forming capability (11) . It was recently demonstrated binding of human Vn by many microbial pathogens involves the Cterminal heparin-binding domain (residues 352-374). However, this interaction reportedly does not interfere with Vn-mediated inhibition of C5b-9 deposition (12) .
In this study of Vn-C9 complement interactions, we employed goat Vn as a model in a homologous system for two reasons. First, goat Vn possesses one more RGD motif than other species, including humans (13); this feature may influence protein functions. Second, bacterial pathogenesis is important in animal husbandry and modulation of C9 function may play a significant role in host innate immunity.
MATERIALS AND METHODS

Materials
Reagents used in this study were of analytical grade. DEAE-Sepharose, Coomassie Brilliant Blue R 250, PMSF, heparin-Sepharose, RGD peptide and Ni-NTA agarose were procured from Sigma-Aldrich (St Louis, MO, USA); PEG 4000 from BioBasic Canada (Markham, ON, Canada); acrylamide, SDS, Tris and nitrocellulose membrane from Bio-Rad Labs (Richmond, CA, USA); restriction enzymes from New England BioLabs (Ipswich, MA, USA); pPROExHTa prokaryotic expression system from Life Technologies (Carlsbad, CA, USA); and a PrepEase gel purification kit from USB (Cleveland, OH, USA).
Proteins
Complement C9
Complement C 9 was purified from goat serum in accordance with a published protocol for human and bovine C9 with modifications (14, 15) . In brief, goat serum with 0.5 mM PMSF was centrifuged at 3000 g at 4°C for 10 min to pellet aggregates formed during cold storage. All subsequent steps were performed at 4°C with solutions containing 0.5 mM PMSF and 0.03% sodium azide.
In the initial experiment, serum was subjected to BaCl 2 and two cycles of PEG 4000 fractionation followed by DEAE-Sepharose and Vn-Sepharose chromatography in sequence. In subsequent experiments, the DEAE-Sepharose chromatography step was omitted; this did not affect protein purity. Presence of C9 in fractions was confirmed by western blot using rabbit anti-human C9 polyclonal antibody (H-210 rabbit polyclonal Ig-G; Santacruz, Dallas, TX, USA) .
Goat Vn
Vn was purified essentially as described previously (13) and is briefly outlined below. Goat plasma with 1 mM PMSF was fractionated on Sepharose 4B and heparinSepharose columns sequentially in the presence of 20 mM sodium phosphate, pH 7.4, containing 110 mM NaCl. Urea (6 M) and dithiothreitol, 10 mM, were added to the adsorbed plasma and kept at room temperature (25°C) for 3 hr and then fractionated on a heparinSepharose column containing urea. The column-bound Vn was eluted by increasing the NaCl concentration to 1 M. Fractions were analyzed for the presence of Vn by western blot and those containing Vn were dialyzed against PBS.
Recombinant Vn fragments
Escherichia coli cultures with genes representing the Nand C-termini of goat Vn (601 bp from the N-terminus and 472 bases from the C-terminus respectively) were available in our laboratory (13) . Glycerol stocks of bacteria were revived, grown and protein-purified. An Ni-agarose column was used for the N-terminal Vn fragment, whereas heparin-Sepharose chromatography was performed to isolate the C-terminal Vn fragment (13) . Purified Vn fragments were analyzed by western blot and urea removed by slow dialysis against PBS.
RGD mutant Vn
Goat Vn has two RGD motifs; the first (RGD-1) represents residues 45-47 and the second (RGD-2) is positioned at 106-108 residues (13) . Three RGD mutant Vn clones were generated. In the first, the RGD-1 was altered to GGD-1 (clone M1) whereas the second clone (M5) had AGD-2 and the third clone (M9) an RGA-2 sequence instead of RGD-2 (16). The RGD mutant Vn was generated by overlap extension PCR-based sitedirected mutagenesis. For each mutant, there was essentially a pair of overlapping complementary primers with mutated nucleotides in the middle of the primers (M F , mutant forward and M R , mutant reverse). In addition, there was a pair of flanking primers, the normal forward (N F ) and reverse (N R ) primers used for wild Vn. A total of four primers were required to generate each mutant (Table 1) . Three PCR reactions were performed for each mutant. In the first PCR reaction, M F and N R primers and wild Vn template were used to generate amplicon 1. In the next PCR cycle, primers M R and N F and wild Vn template were employed to generate amplicon 2. Both amplicons were then gel purified. In the last PCR reaction, the extracted amplicons 1 and 2 were used as templates without any primer for 10 cycles followed by addition of normal primers, N F and N R, and continuation of cycles ( Table 1 ). The amplicons and vector, pPROExHTa, were digested with EcoR1 and Hind III followed by purification employing a PrepEase gel purification kit. Approximately 30 ng of insert was ligated to 50 ng of vector employing T4 DNA ligase; the ligated product was used to transform DH5 a E. coli, followed by screening of positive clones. One of the positive clones was bulk cultured; then induced with isopropyl b-D-1-thiogalactopyranoside for protein expression. The bacterial pellets were extracted with 20 mM sodium phosphate (pH 7.4), 100 mM NaCl, 10 mM EDTA (pH 7.5) and 1 mM PMSF at 4°C and then centrifuged at 26,000 g for 30 min. The pellets were extracted with 8 M urea and 10 mM dithiothreitol in the above buffer at room temperature for 2 hr. The extract was centrifuged and the supernatant used for protein purification. Mutant Vns were purified employing heparin-Sepharose matrix, as described above.
Complement C9-Vn interaction
Microtiter plate assay
The wells of a microtiter plate were coated by adding 100 mL of C 9 protein (20 mg/mL) in carbonate buffer (pH 9.6) overnight at 4°C. The wells were emptied by suction and washed four times with PBS. Free sites on the wells were blocked with 100 mL of 1% gelatin and incubated for 1 hr at room temperature, after which the wells were emptied and washed with PBS-T. Varying concentrations of Vn were added and the plates incubated at room temperature for 2 hr. The wells were then washed with PBS-T followed by the addition of rabbit anti-goat Vn antiserum (1:3000 dilution in PBS-T). After 2 hr, the wells were washed and 100 mL of goat anti-rabbit IgG-peroxidase conjugate (1:3000 dilution) added. The plates were incubated for another hour followed by several PBS-T washings. Activity of bound peroxidase was assessed by adding O-phenylene diamine. The color produced was read at 492 nm in a microplate reader.
The effect of heparin and RGD peptide on C9-Vn interactions was studied by adding these components to the wells at the time of Vn addition. Final concentrations of these substances were 500 ug/mL.
Blot overlay assay
Following SDS-gel electrophoresis, C9 or Vn protein was transferred to nitrocellulose membranes. Free sites on the membranes were blocked with skim milk powder. The strips with immobilized C9 were incubated with Vn or its fragments in PBS overnight at 4°C. In the reverse assay, membranes with immobilized Vn or fragments were incubated with C9. Following PBS-T washings, the membranes with immobilized C9 were incubated with rabbit anti-goat Vn antiserum (1:500 dilution) for 2 hr at room temperature whereas strips with immobilized Vn were treated with anti-C9 antibody (1:250 dilution). After PBS-T washings, the membranes were incubated with secondary antibody conjugated to peroxidase for 2 hr. After several washings, peroxidase activity was measured by adding diaminobenzidine. 
CAG CCC AGG GTC TGA GTC TCC Cgc CCC AGG TGA TGG GGC
The letters in lower case represent the substituted nucleotides. F, forward; MF, mutagenic forward; MR, mutagenic reverse; R, reverse.
Primers for amplification of wild vitronectin
CCC AAG CTT CTA AGC GAT GGA GCG TGG GTA GG EcoRI and HindIII sites have been appended to the forward (NF) and reverse primers (NR), respectively, and have been underlined.
Vn and bacterial growth
E. coli strain DH5a, preserved as glycerol stock, was revived and used for analyzing Vn-mediated growth modulation. The revived culture was sub-cultured in fresh LB at 1:100 dilutions and grown till A 600nm reached 0.4. One ml of E. coli culture was centrifuged at 3000 g for 5 min at 4°C. The pellets were mixed with 500 mL of fresh goat serum and 500 mL Vn (50 mg/mL) and incubated at 4°C for 1 hr. The suspension was the centrifuged at 3000 g for 5 min and the bacterial pellets washed twice with saline and suspended in 1 mL saline. Serial dilutions of this suspension from 1:10 were prepared and 10 mL from each dilution streaked on agar plates. The plates were incubated at 37°C overnight and the numbers of bacterial colonies formed counted. The positive control included fresh goat serum and the negative control had only PBS.
Nucleotide sequencing
Sequencing of selected clones was outsourced to Bioserve Technology (Hyderabad, Andhra Pradesh, India).
RESULTS
Proteins
Complement C9
C9 was purified by a combination of salt/PEG fractionation and anion-exchange chromatography followed by separation on a Vn-Sepharose column. The recovered protein had an apparent size of 66 kDa in SDS gel (Fig. 1a) . In addition, a prominent band of 180 kDa was seen. A low intensity high molecular weight band that may represent polymer was also observed; C9 has a tendency to polymerize (1) . The authenticity of C9 protein is based on the following facts. First, the protocol used for goat C9 isolation was based on methods developed for human and bovine C9 protein. Second, goat C9 reacted with rabbit anti-human C9 polyclonal antibody and also reacted with bovine C9 protein (Fig. 1b) . Third, bovine and human C9 are of similar size, 66 kDa (14, 15) . Furthermore, sequence similarity of C9 among these species is quite high; bovine and human share 81% identity whereas goat and human C9 have 69% similarity.
Vn
Vn was isolated from goat blood and showed a prominent band of 81 kDa in SDS gel. In addition, high molecular weight multimers were detected (Fig. 2a) .
These results are in agreement with earlier studies (13) . For generation of Vn mutants, recombinant full length plasmid (pVnFl) was isolated and the sequencing results revealed two RGD motifs at positions 45-47 and 106-108. This plasmid served as template for subsequent mutation experiments. Sequencing of mutated clones revealed desired mutations. Clone M1 had first RGD altered; R being replaced by G. However, two undesired alterations were also observed; W in place of C at 267 residue and T for M at 400 position. Clone M5 had R106 replaced with A (AGD2). In addition, P440 had been changed to L 440. In the third mutant, M9, D 108 was replaced with A (RGA2) with no other alterations. The mutant Vn were eluted from the heparin-Sepharose column at 1 M NaCl and found to have >90% purity in SDS gel, with an apparent size of 68 kDa (Fig. 2b) . About 2 mg of each mutant Vn were recovered from one liter of bacterial culture. The Nand C-fragments of Vn were also successfully purified. As expected, the N-fragment was 40 kDa in size,whereas the C-fragment showed a band of 22 kDa in SDS gel ( Fig. 2c) (13) .
Vn-C9 interaction
Three lines of evidences indicate C9 binding to Vn. First, C9 was purified using Vn-Sepharose columns, bound to the columns and was eluted with high salt (Fig. 1) . Second, blot overlay assay confirmed the above observation: C9 reacted with the Vn immobilized onto the nitrocellulose membranes, as evidenced by staining of the 81 kDa polypeptide and multimers (Fig. 3a) . Multimers also react faintly, but disappear on membrane drying. In addition, a weakly stained band in the 160 kDa region may have represented Vn dimer; Vn is known to form dimers spontaneously (17) . In the control lane with no added C9, anti-C9 antibody did not react with Vn. Nand C-fragments were also analyzed for C9 binding activity. C9 bound only to the N-fragment of Vn as evidenced by staining in the 40 kDa region; no staining was observed in the lane representing the C-fragment (Fig. 3a) . These results were supported by reverse blot overlay assays in which immobilized C9 was incubated with Vn or its fragments. As shown in Figure 3b , Vn and its N-terminal fragment interacted with C9 as evidenced by the staining pattern. No binding was observed with the C-fragment of Vn.
C9-Vn interaction was also evident in the microtiter plate assay. In this assay, concentration-dependent binding of Vn to plastic immobilized C9 was observed (Fig. 4a) . When Vn fragments were evaluated, the N-fragments showed concentration-dependent enhanced binding to immobilized C9. This kind of enhancement was not noted with the C-fragment (Fig. 4b) . The involvement of RGD motif and the heparin binding domain of Vn in C9 binding were also evaluated by microtiter plate assay. Inclusion of soluble RGD peptide (500 ug/mL final concentration) significantly reduced C9-Vn interactions at all concentrations of Vn tested (Fig. 4c) . However, with heparin (500 ug/mL), no significant inhibition of C9-Vn interaction was observed. These results imply that the RGD sequence towards the N-terminus of Vn may be involved in binding to C9 complement.
RGD mutant Vn and C9 binding
Based on the above results, an attempt was made to identify the RGD motif of Vn that is involved in binding to C9. Bioinformatics analysis (18) indicated that the second RGD has surface orientation whereas the first RGD sequence may be cryptic. With this information, the charged residues of the second RGD motif were altered by site-directed mutagenesis and the Vns derived tested for C9 binding. Both the Vns, namely RGA-2 and GGD-2, showed significantly less binding than wild Vn; this feature being more pronounced with the GGD-2 Vn. With these facts, the R of the first RGD was altered to generate GGD-1 Vn, which was found to show binding to C9 that was almost comparable to that observed with the wild Vn (Fig. 5) . These results imply that the second RGD-2 of goat Vn is the C9 binding site.
Bacterial growth in the presence of Vn
As evidenced by the number of colonies formed, E. coli DH5a grew drastically less in the presence of fresh goat serum than in the PBS control. At 1:10 À4 dilutions, there were about 78 Â 10 2 CFU/mL of the culture in the control whereas there were only about 1 Â 10 2 when serum was included (Fig. 6 ). These results demonstrate an inhibitory effect of fresh serum on E. coli and are in agreement with earlier observations that suggest involvement of natural antibody and complement components of fresh serum are required for bactericidal activity (19) . De-complementation of serum at 56°C for 30 min resulted in growth patterns similar to the PBS control. The effect of Vn on bacterial growth was then tested. Vn alone (without serum) reduced E. coli growth to about half that in the PBS-treated group, suggesting that Vn has bactericidal properties. Vn in combination with serum further reduced E. coli growth, as expected given that the presence of complement proteins in fresh serum would add to retardation of bacterial growth. Because serum and Vn independently inhibit bacterial growth it was expected that the serum-Vn combination would retard E. coli growth maximally. However, this combination resulted in less inhibition than in the serum control group, probably because Vn-C9 interaction limited the anti-bactericidal activity of these proteins. Vn fragments were also tested for their effect on bacterial growth. Both the fragments, N-and C-, reduced bacterial growth to some extent in serum free conditions. The fragment(s)-serum combination further reduced E. coli growth.
DISCUSSION
In this study, an attempt was made to evaluate Vn-C9 interaction using goat homologous system. Three independent assays (affinity chromatography using Vn-Sepharose, blot overlay and ELISA) demonstrated Vn binding to purified C9. Furthermore, using recombinant fragments, the C9 binding site was mapped to the N-terminus of Vn. It has previously been suggested that the HBD (HBD-3) of Vn is involved in C9 binding. This assumption is based on the facts that the peptides correspond to residues 348-379 of human Vn and represent HBD-3 inhibited C9 binding and its pore forming capability. Also, the CNBr-generated fragment possessing the HBD reportedly inhibits C9 mediated cytolysis (8, 10) . Sheehan et al. subsequently demonstrated that a 12 kDa heparin binding fragment generated after CNBr digestion of human Vn does not bind to C5b-7 complex nor induce C9 polymerization, suggesting involvement of non-heparin binding domain(s) of Vn in complement inhibition (9) . In the present study, involvement of the non-heparin binding region of goat Vn in C9 binding was amply established in that the soluble exogenous heparin had no effect on C9-Vn interaction. Also the C-fragment with HBD-3 did not support C9 binding whereas C9 did bind to the N-fragment that lacked HBD-3, the primary heparin binding region of Vn.
Further, the following observations indicate involvement of the non-heparin binding site of Vn in C9 binding. First, inhibition of C9 binding to Vn in the presence of added RGD peptide suggests involvement of this sequence in C9-Vn interaction. These observations support C9 binding to the N-fragment of Vn, which possesses two RGD motifs. Further, precise mapping of the C9 binding site was achieved by generating RGD mutant Vns; alterations of charged residues in the second RGD sequence significantly reduced C9 binding. These results indicate chargecharge interactions during C9 binding to Vn. Because the alteration of R in the second RGD sequence caused maximum reduction in C9 binding to Vn, the R of the first RGD was changed to G. No reduction of C9 binding to mutated Vn was observed, suggesting that this sequence is not involved in C9-Vn interaction. There are conflicting reports on the orientation of the RGD motif in human Vn. A number of studies suggest that the RGD sequence is accessible for cell adhesion and that this sequence may therefore have surface deposition (20) . In contrast, Seiffert and Smith have provided evidence in support of cryptic RGD in human Vn (21) . In the absence of structural data, sequence analysis on the PROTEAN program of DNA STAR (18) depicts surface orientation of RGD-2 whereas the RGD-1 is cryptic, which further lends support to the present findings.
The consequences of C9-Vn interaction in terms of functionality was assessed by measuring bacterial growth. It has been observed that several bacteria (Streptococci, Staphylococcus aureus, E. coli) bind specifically to human Vn (22) . We have also observed binding of S. aureus and E. coli to goat Vn (pers. comm., Joshi et al., 2016). In the presence of fresh goat serum, growth of E. coli DH5a is drastically reduced as a result of interference by natural antibody and complement proteins (19) . When Vn or its fragments were added along with serum, bacterial growth was greater than in the serum alone control. These results are as expected because Vn and its N-fragment are capable of binding C9 and therefore non-availability or reduction in C9 would support bacterial growth. However, the results with the C-fragment of Vn are unexpected. First, no binding of this fragment to C9 was observed in two different assays, which should have meant maintenance of normal C9 concentrations leading to growth inhibition. Second, recent reports have indicated that HBD has anti-microbial properties (23, 24) . Because the primary heparin binding site (HBD-3) is present in the C-fragment, this fragment should be capable of inhibiting bacterial growth. The enhanced growth in the presence of C-fragment suggests its interaction with some serum component(s) that is also involved in inhibiting bacterial growth. This assumption needs further investigation. 
